201 Study for patients with Myelofibrosis

The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of INCB050465 and Ruxolitinib in subjects with myelofibrosis. To obtain further study eligibility details and locate a clinical research site that is participating in this study, please call the Incyte Corporation Call Center [Phone: (855) 463‐3463] or review the additional study information on clinicaltrials.gov

Study Sponsor:
Incyte Corporation